Allergan Fortifies Defenses In Response To Valeant’s Hostile Bid
This article was originally published in The Gray Sheet
Executive Summary
Allergan’s board adopted a so-called poison pill stockholder rights plan to hold off Valeant’s hostile takeover effort while it reviews the unsolicited offer.